Does MS Cause a Positive ANA Test? The Connection Explained

Multiple sclerosis does not directly cause a positive ANA (antinuclear antibody) test in the way that lupus does, but people with MS test positive for ANA at higher rates than the general population. Studies report ANA positivity in anywhere from about 17% to 43% of MS patients, compared to roughly 7–16% of healthy people. The relationship is real but indirect, rooted in shared immune dysfunction and overlapping genetic risk factors rather than MS itself generating those antibodies. Understanding why this happens matters, because a positive ANA during an MS workup can cause confusion and anxiety.

How Common Is a Positive ANA in People with MS?

The reported rates vary quite a bit depending on how the study was designed and what cutoff was used. A large 2025 study of 364 people at their first suspected MS episode found that about 16.5% tested ANA-positive.¹ A smaller French study of 82 confirmed MS patients found ANA in nearly 43%.² An Egyptian case-control study found roughly 75% of MS patients had some level of ANA positivity, though the control group was also high at 65%, and the difference between the two groups was not statistically significant.³

One review of prior research noted that ANA prevalence in MS patients has been reported anywhere from 2% to 44%.⁴ That enormous range reflects differences in the testing method used, the titer threshold chosen, and the patient population studied. Still, even the lower estimates sit above what you would expect if MS and ANA had nothing to do with each other.

Why People with MS Test ANA-Positive More Often

MS is fundamentally a disease of immune misdirection. The immune system attacks the protective covering of nerves in the brain and spinal cord. That same tendency toward immune overactivity can spill over into producing autoantibodies that target cell nuclei, which is exactly what ANA are. But the connection goes deeper than just generalized immune chaos.

A 2025 study published in Scientific Reports looked specifically at what drives ANA positivity in early MS and found two strong associations. The first was Epstein-Barr virus (EBV) exposure. People who were ANA-positive had antibody levels against a specific EBV protein that were roughly 2.5 times higher than those in ANA-negative participants.¹ EBV infection is already considered a near-necessary trigger for MS, and it also plays a role in other autoimmune conditions. This overlap hints that EBV exposure primes the immune system to produce a broader range of autoantibodies, not just the ones involved in MS.

The second association was genetic. ANA-positive participants were significantly more likely to carry two copies of a particular immune gene variant called HLA-DRB1*15:01, about 13% compared to under 3% in ANA-negative participants.⁵ This gene variant is one of the strongest known genetic risk factors for MS, and it also shows up in lupus research. The researchers interpreted ANA in early MS not as a sign of a second disease but as a marker of shared risk factors between MS and lupus. In other words, the same genetic and environmental cards that increase someone’s chances of developing MS also make it more likely they will produce ANA, without those antibodies meaning lupus is present.

ANA positivity was also more common in women within the MS population, which mirrors the pattern seen in both MS itself and in ANA positivity in healthy people.¹ The female sex bias in autoimmunity is well established and adds another layer to why a woman with MS is particularly likely to get an ANA result that raises questions.

What the ANA Test Typically Looks Like in MS

If you have MS and your ANA comes back positive, the details of the result can tell your doctor a lot about whether to be concerned. ANA tests report both a titer (how concentrated the antibodies are) and a pattern (how the antibodies light up under a microscope).

In MS, ANA titers tend to be low. A classic study in JAMA Neurology found that titers in MS patients ranged from 1:8 to 1:32, and rarely went above 1:8 in the healthy control group.⁶ For context, many labs consider titers of 1:40 or below to be clinically insignificant, and lupus patients typically show much higher titers, often 1:160 or above. A low-titer positive ANA in someone already diagnosed with MS is common and rarely points to a second autoimmune condition.

The staining patterns seen in MS also differ from what clinicians look for in lupus. The most common patterns in MS patients were diffuse, fine-speckled, and a combination of the two.⁶ Lupus more often produces a homogeneous or a rim (peripheral) pattern, along with specific follow-up antibodies like anti-dsDNA or anti-Smith that are not typically elevated in MS. A fine-speckled, low-titer ANA in someone with clear MS features is far more likely to reflect generalized immune activation than a connective tissue disease.

Does a Positive ANA Mean You Actually Have Lupus?

This is the worry that drives most of the anxiety around ANA results in MS patients, and the short answer is almost certainly not. MS and systemic lupus erythematosus (SLE) are both autoimmune, both more common in women, and both can produce brain and spinal cord symptoms. But having both conditions simultaneously is extraordinarily rare. A case report published in 2023 noted that only 18 cases of MS and SLE coexisting in the same patient have ever been recorded worldwide.⁷

That said, the two diseases do share some underlying biology. A large Swedish study examining family clustering of immune-mediated diseases found that lupus was among several conditions that showed a familial association with MS, meaning that having relatives with lupus slightly increases the statistical chance of developing MS, and vice versa.⁸ This shared genetic ground explains why ANA can pop up in both conditions without meaning both are present.

A study of people at the earliest stage of suspected MS (clinically isolated syndrome) found that 20% had a positive ANA and a few had other autoantibodies, but none of them met criteria for lupus, Sjögren’s syndrome, or antiphospholipid syndrome.⁹ This is a reassuring finding for anyone early in the diagnostic process. The ANA on its own, without additional clinical signs and specific lupus antibodies, does not change the diagnosis.

Why ANA Testing Happens During an MS Workup

If ANA is so commonly positive in MS and does not usually signal lupus, you might wonder why doctors order it at all. The answer is that ANA testing is part of ruling out conditions that can mimic MS. Lupus, Sjögren’s syndrome, and other connective tissue diseases can all cause white matter lesions in the brain and spinal cord that look similar to MS plaques on an MRI. Before confirming a diagnosis of MS, neurologists need to exclude these mimics.

German neurological guidelines, for example, list ANA as a mandatory lab test in the MS diagnostic workup, along with anti-dsDNA antibodies.¹⁰ The goal is not to diagnose lupus in every MS patient. It is to catch the occasional patient whose neurological symptoms are actually being caused by a systemic autoimmune condition rather than MS. When the ANA is low-titer with a nonspecific pattern and there are no other lupus features (joint inflammation, skin rashes, kidney problems, specific antibodies), clinicians can move forward with confidence that MS is the correct diagnosis.

Trouble arises when a positive ANA result is over-interpreted, either by the patient or by a provider unfamiliar with how common these results are in MS. A case series of six patients with diagnostic overlap between MS and connective tissue diseases highlighted how tricky this can be, noting that ANA was positive in all cases, even those ultimately confirmed as MS.⁴ The ANA by itself does not settle the question. It is the broader clinical picture, including symptoms, imaging, spinal fluid analysis, and more targeted antibody tests, that determines the diagnosis.

Can MS Medications Trigger a Positive ANA?

Yes, and this is an underappreciated source of confusion. Interferon-beta, one of the older disease-modifying therapies for MS, has been linked to the development of new autoantibodies in patients who did not have them before treatment. A study from 1999 tracked MS patients on interferon beta-1b and found that autoantibodies, including ANA, anti-smooth muscle antibodies, and anti-thyroid antibodies, appeared in 13 treated patients but not in the untreated controls. In several cases, these antibodies were accompanied by changes in thyroid or liver function.¹¹

Interferons are well-established triggers of drug-induced lupus, a condition where lupus-like symptoms and antibodies develop during treatment and resolve after the drug is stopped. More than 90 drugs have been identified as potential triggers for this phenomenon, including interferons and TNF-alpha inhibitors.¹² For someone with MS who develops a new positive ANA while on interferon therapy, the timing relative to treatment is an important clue. If the antibodies were not present before starting the medication, drug-induced autoimmunity is a more likely explanation than an emerging second autoimmune disease.

Newer MS therapies work through different mechanisms, and their relationship to ANA development is less well characterized. If you are on any MS treatment and get a new ANA result, flagging the specific medication to your neurologist helps them put the result in context.

Does a Positive ANA Change How MS Behaves?

This is one of the more reassuring findings in the literature. The presence of ANA does not appear to make MS worse. A study that looked at whether elevated autoantibodies predicted a more severe disease course in MS patients found no significant difference in outcomes between those with and without autoantibodies.¹³ A separate study came to a similar conclusion, finding that ANA positivity did not correlate with gender, age, disease duration, MS subtype, or disability level.¹⁴

There is one nuance. That same study did find that when individual patients were tested at two different time points, ANA tended to appear during periods of active disease. The researchers suggested this reflects surges of immune activation during relapses rather than ANA having any role in causing those relapses.¹⁴ Think of it as the immune system running hot across the board during a flare-up, producing extra autoantibodies as a side effect rather than as a driver of new damage. The early MS cohort study from 2025 reached a compatible conclusion, finding that ANA-positive and ANA-negative participants had similar clinical characteristics and similar early disease trajectories.¹

In practical terms, a positive ANA does not mean your MS is going to progress faster or respond differently to treatment. It is a serological curiosity, not a warning sign about prognosis.

How Common Is ANA Positivity in Healthy People?

One piece of context that often gets lost is just how common ANA is in people who have no autoimmune disease at all. A large U.S. population study using nationally representative data found that ANA prevalence in the general population rose from about 11% in the late 1980s to nearly 16% by 2011–2012, corresponding to roughly 41 million ANA-positive Americans in that most recent survey period.¹⁵ Women were two to three times more likely to test positive than men, and older adults were more likely to test positive than younger ones.¹⁵

A study from China found an ANA-positive rate of about 7% in a healthy population, with women again testing positive at more than double the rate of men.¹⁶ ANA in healthy individuals has been associated with older age, female sex, and certain infections, and it tends to remain at low titers without ever progressing to a diagnosable autoimmune condition.¹⁷

Knowing that somewhere between 1 in 7 and 1 in 14 healthy adults will test ANA-positive puts the MS numbers into perspective. When studies report that 17% or even 43% of MS patients have ANA, part of that proportion would have tested positive regardless of their MS diagnosis, simply because of their sex, age, or prior EBV exposure. The excess positivity attributable to MS-specific immune dysfunction exists, but it sits on top of a high background rate.

When to Be Concerned About ANA Results

A positive ANA deserves further investigation when certain red flags accompany it. For someone in the process of being evaluated for MS, the following patterns suggest the possibility of a connective tissue disease mimicking MS rather than MS itself:

High titers: ANA at 1:160 or above, especially 1:320 or higher, warrants a closer look at lupus and related conditions.
Specific follow-up antibodies: Positive anti-dsDNA, anti-Smith, anti-Ro, or anti-La antibodies point toward lupus or Sjögren’s syndrome rather than MS.
Systemic symptoms: Joint pain, skin rashes (especially a butterfly-shaped facial rash), mouth sores, hair loss, or kidney problems alongside neurological symptoms raise the probability of a systemic autoimmune condition.
Low complement levels: Complement proteins (C3 and C4) tend to drop during active lupus. In the clinically isolated syndrome study mentioned earlier, no patients with positive ANA had low complement.⁹

If none of those features are present, a low-titer ANA with a diffuse or fine-speckled pattern in someone whose MRI and clinical picture fit MS is essentially a non-finding. It does not require repeated monitoring, does not need to be retested at each office visit, and should not delay MS treatment. The strongest takeaway from the research is that ANA in MS is a reflection of an overactive immune system doing what overactive immune systems do, not a second diagnosis waiting to happen.

1
Scientific Reports. Antinuclear antibodies in early multiple sclerosis reflect systemic lupus erythematosus shared risk factors
2
PubMed. Antinuclear antibodies positivity is not rare during multiple sclerosis and is associated with relapsing status and IgG oligoclonal bands positivity
3
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery. Prevalence of antinuclear antibody in patients with multiple sclerosis: a case-control study
4
PubMed Central. A challenging entity: multiple sclerosis or collagen tissue disorders: A case series of 6 patients
5
Scientific Reports. Antinuclear antibodies in early multiple sclerosis reflect systemic lupus erythematosus shared risk factors – Section: Results
6
JAMA Neurology. Antinuclear Antibodies in Multiple Sclerosis
7
PubMed Central. Coexistence of multiple sclerosis and systemic lupus erythematosus – a case report
8
PubMed. Shared aetiology underlying multiple sclerosis and other immune mediated inflammatory diseases: Swedish familial co-aggregation and large-scale genetic correlation analyses
9
PubMed Central. Multiple sclerosis presented as clinically isolated syndrome: the need for early diagnosis and treatment
10
Neurology International Open. Choosing wisely? Multiple Sclerosis and Laboratory Screening for Autoimmune Differential Diagnoses
11
PubMed. Autoimmune events during interferon beta-1b treatment for multiple sclerosis
12
PubMed Central. Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced
13
PubMed. Do elevated autoantibodies in patients with multiple sclerosis matter?
14
PubMed. Frequency and significance of antinuclear antibodies in multiple sclerosis
15
PubMed Central. Increasing Prevalence of Antinuclear Antibodies in the United States
16
PubMed. Antinuclear antibodies in healthy population: Positive association with abnormal tissue metabolism, inflammation and immune dysfunction
17
PubMed Central. Antinuclear antibodies in healthy people and non-rheumatic diseases – diagnostic and clinical implications